iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR) | 2B70Registrer dig for at låse op for ratings |
Fondens performance | 29-02-2024 |
Vækst af 1.000 (DKK) | Avanceret graf |
Fond | 14,1 | 7,5 | -6,3 | 2,8 | 3,5 | |
+/-Kat | -4,7 | 10,6 | 6,5 | 1,5 | -2,1 | |
+/-Indeks | -11,3 | 0,7 | -3,3 | -7,4 | -2,9 | |
Kategori: Sektor - Bioteknologi, Aktier | ||||||
Kategoribenchmark: Morningstar Gbl Biotechnolo... |
Oversigt | ||
Closing Price 29-03-2024 | EUR 5,96 | |
Kursændring 1 dag | 0,00% | |
Morningstar Kategori™ | Sektor - Bioteknologi, Aktier | |
Børs | DEUTSCHER KASSENVEREIN AG GRUPPE DEUTSCHE BOERSE | |
ISIN | IE00BYXG2H39 | |
Markedsværdi i alt (mio.) 28-03-2024 | USD 522,30 | |
Seneste TNA(mio.) 28-03-2024 | USD 477,65 | |
Løbende omkostning 19-09-2023 | 0,35% | |
Investeringsstrategi | Passiv |
Investeringsmålsætning: iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR) | 2B70 |
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. |
Returns | |||||||||||||
|
Management | ||
Manager navn Startdato | ||
- - | ||
Startdato 19-10-2017 |
Annonce |
Kategoribenchmark | |
Fondens indeks | Morningstar indeks |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Formuefordeling iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR) | 2B70 | 27-03-2024 |
|
|
Top 5 placeringer | Sektor | % |
Amgen Inc | Healthcare | 8,42 |
Gilead Sciences Inc | Healthcare | 8,16 |
Regeneron Pharmaceuticals Inc | Healthcare | 8,06 |
Vertex Pharmaceuticals Inc | Healthcare | 7,99 |
Moderna Inc | Healthcare | 4,35 |
Øget Mindsket Ny siden sidste portefølje | ||
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR) | 2B70 |